Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aldara in lentigo maligna
NCT01161888Phase 4Completed
- Start
- Jun 2010
- Primary completion
- Mar 2012
- Modality
- Nucleic Acid-Directed Small Molecules, Irreversible Covalent Inhibitors, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of imiquimod in lentigo maligna (LM). Primary endpoint: Pathological Complete Regression. Started Jun 2010; status: completed.
02
Drugs
imiquimod
03
Conditions
lentigo maligna (LM)
Beyond the preview
Go deeper on NCT01161888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01161888.